Induction of tolerogenic dendritic cells by IL-6-secreting CT26 colon carcinoma
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2011-10-15 / Immunopharmacol Immunotoxicol 2012 Jun;34(3):465-9Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2011-10-04 / Int. J. Oncol. 2012 Jan;40(1):287-98Current vaccination strategies for prostate cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2011-10-03 / Eur. Urol. 2012 Feb;61(2):290-306Proving the principle: dendritic cell-based vaccines in urogenital cancers
/in Dendritic Cells, Hypernephroma, International Publications, Prostate Cancer /von 2011-10-01 / Expert Rev Vaccines 2011 Oct;10(10):1355-7Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2011-09-28 / Clin. Dev. Immunol. 2011;2011:249281Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer : an open-label comparative cohort trial
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2011-09-19 / Strahlenther Onkol 2011 Oct;187(10):619-25A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2011-09-17 / Cancer Immunol. Immunother. 2012 Mar;61(3):373-84Current immunotherapeutic approaches in pancreatic cancer
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2011-09-14 / Clin. Dev. Immunol. 2011;2011:267539Immunotherapy in human glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2011-08-31 / Rev. Neurol. (Paris) 2011 Oct;167(10):668-72IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de